Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{172010,
        author = {Ankita Dattatray Patil and Vaishnavi Sanjay Bhandawalkar and Prachi Vijay Joshi and Divya Baban Chaudhari and Dolly Bhagwan Chaudhari and Harshali Yuvraj Chaudhari},
        title = {Treatment resistance in Genitourinary Cancer},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {8},
        pages = {1625-1627},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=172010},
        abstract = {Treatment resistance in genitourinary (GU) cancers, including prostate, bladder, and kidney cancers, significantly limits the effectiveness of therapies, leading to disease progression. Resistance mechanisms include enhanced DNA repair, metabolic reprogramming, altered apoptotic pathways, immune evasion, and genetic adaptations. Chemotherapy, immunotherapy, and targeted therapies are frequently undermined by these mechanisms. Emerging strategies to overcome resistance involve combination therapies, targeting specific molecular pathways, and personalized medicine approaches. Recent advances, such as the role of circular RNAs and novel agents like belzutifan, offer promising avenues to counteract resistance and improve patient outcomes.},
        keywords = {Gemcitabine, Doxorubicin, Cisplatin,  Bladder cancer ,Kidney cancer, Renal cancer, Circular RNA},
        month = {January},
        }